Vital signs: lipid regulators were the third-best-selling drug class in 2010

J U L Y 2 0 1 1 • C A R D I O L O G Y N E W S
HEART OF THE MATTER
President, IMNG Alan J. Imhoff
Editor in Chief Mary Jo M. Dales
Executive Director, Operations Jim Chicca
placebo group, in order to reach a target Director, Production/Manufacturing Yvonne
Executive Editors Denise Fulton, Kathy Scarbeck
and Blood Institute announcedthat the Atherothrombosis In- Managing Editor Catherine Hackett
Production Manager Judi Sheffer
niacin plus statin was reported to be more Senior Editors Christina Chase, Kathryn
Production Specialists Maria Aquino, Anthony
effective than ezetimibe plus statin in re- Keith Haglund, Gina L. Henderson, Sally Koch Creative Director Louise A. Koenig
Design Supervisor Elizabeth Byrne Lobdell
ing terminated because of the futility of the ARBITER 6-HALTS study (N. Engl. J.
Jane Salodof MacNeil, Renée Matthews,Catherine Cooper Nellist, Amy Pfeiffer, Terry Senior Designers Sarah L.G. Breeden, Yenling Liu
showing benefit, the study’s failure made Designer Lisa M. Marfori
Editorial Production Manager Carol Nicotera-Ward
Photo Editor Catherine Harrell
Web Production Engineer Jon Li
Associate Editors Felicia Rosenblatt Black,
lation, and interested public ask “why?” at until the full results of AIM-HIGH are re- Therese Borden, Lorinda Bullock, Jay C.
Web Production Specialist Jennifer Calhoun
ported before integrating the findings into Cherniak, Richard Franki, Virginia Ingram-Wells, Jane Locastro, January W. Payne their clinical practice, and that patients Sales Director, IMNG
Reporters Chicago: Patrice Wendling; Denver:
National Account Manager
Philadelphia: Mitchel L. Zoler; San Diego: Doug Brunk; San Francisco: Sherry Boschert, Advertising Offices 60 Columbia Rd.,
Robert Finn; Washington: Alicia Ault, Frances Correa, Elizabeth Mechcatie, Naseem S.
Miller, Heidi Splete, Miriam E. Tucker, Kerri Classified Sales Manager, IMNG
Multimedia Producer Nick Piegari
Contributing Writers Christine Kilgore,
Classified Sales Representative
A N T O N I O M .
Project Manager Susan D. Hite
G O T T O J R . , M . D .
Assignments Manager Megan Evans
Reprints/Eprints
Editorial Offices 5635 Fishers Lane, Suite
sufficiently powered. A clinical trial cur- with the cholesteryl ester transfer protein Sr. Program Manager, Customized Programs
cetrapib, so the final results are far from Audience Development Manager Barbara Cavallaro,
Address Changes Fax change of address (with
old mailing label) to 973-290-8245 or e-mail Program/Marketing Manager Jennifer Eckert
Business Controller Dennis Quirk
Director of Information Technology Doug
Adv. Services Manager Joan Friedman
Credit Supervisor Patricia H. Ramsey
Senior Systems Administrators Lee J. Unger,
raising HDL will be beneficial, and there Manager, Administration/Conventions Lynne
aims to enroll 25,000 subjects, so this dif- Systems Administrator/Application Support
Receptionist Linda Wilson
Accounts Payable Coordinator Daniela Silva
must indicate large differences in expect- support for the “HDL hypothesis,” but CARDIOLOGY NEWS is an independent newspaper neither does it drive the final nail in the that provides the practicing specialist with timely old mailing label) to CARDIOLOGY NEWS Circula- and relevant news and commentary about clinical tion, 60 Columbia Rd., Bldg. B, 2nd flr., Morris- decrease in events reported with niacin in developments in the field and about the impact of the Coronary Drug Project ( J. Am. Coll.
health care policy on the specialty and the CARDIOLOGY NEWS (ISSN 1544-8800) is published DR. GOTTO is the Stephen and Suzanne monthly by International Medical News Group, background of placebo. Statins have set a Weiss Dean and Professor of Medicine at LLC, an Elsevier company, 60 Columbia Rd., Bldg. very high bar for efficacy, and it can be dif- Weill Cornell Medical College, New York. He B, 2nd flr., Morristown, NJ 07960, 973-290-8200, fax EWS do not necessarily reflect those of the Publisher. International Medical News Group, 973-290-8250. Subscription price is $114.00 per year. ficult to demonstrate incremental benefit is a consultant for AstraZeneca, KOWA, and LLC, an Elsevier company, will not assume Copyright 2011, by Elsevier Inc. with an add-on to statin therapy, as was the Merck; sits on the Board of Directors for responsibility for damages, loss, or claims of any Aegerion Pharmaceuticals and Arisaph kind arising from or related to the information ibe. In fact, there was substantial use of Pharmaceuticals; and is a member of contained in this publication, including any claimsrelated to the products, drugs, or services INTERNATIONAL
advisory boards for DuPont and Vatera MEDICAL NEWS
Lipid Regulators Were the Third–Best-Selling
Drug Class in 2010
Oncologics
40% increase in the risk of bladder cancer. Respiratory agents
crease the risk of bladder cancer, the Food da), is also available in combination with Lipid regulators
Antidiabetes agents
Antipsychotics
most 200,000 patients with type 2 diabetes not be used in patients with active bladder Antiulcerants
found that overall, there was no increased cancer, and that it be used cautiously in pa- Antidepressants
risk of bladder cancer pioglitazone users tients with a history of bladder cancer.
Autoimmune agents
ment for age, sex, smoking, use of other di- HIV antivirals
abetes medications, and other risk factors.
authorities in June to suspend the use of Angiotensin II receptor
blockers
However, the risk did increase with higher ties to proscribe starting pioglitazone treat- Note: Figures represent U.S. wholesale revenue in billions.
Source: IMS Institute for Healthcare Informatics –Elizabeth Mechcatie

Source: http://sandbox.skinandallergynews.com/fileadmin/content_pdf/card/archive_pdf/vol9iss7/70205_main.pdf